Laura Alaimo1,2, Zorays Moazzam1, Zachary J Brown1, Yutaka Endo1, Andrea Ruzzenente2, Alfredo Guglielmi2, Luca Aldrighetti3, Matthew Weiss4, Todd W Bauer5, Sorin Alexandrescu6, George A Poultsides7, Shishir K Maithel8, Hugo P Marques9, Guillaume Martel10, Carlo Pulitano11, Feng Shen12, Olivier Soubrane13, Bas Groot Koerkamp14, Itaru Endo15, Timothy M Pawlik16,17. 1. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. 2. Department of Surgery, University of Verona, Verona, Italy. 3. Department of Surgery, Ospedale San Raffaele, Milan, Italy. 4. Department of Surgery, Johns Hopkins Hospital, Baltimore, MD, USA. 5. Department of Surgery, University of Virginia, Charlottesville, VA, USA. 6. Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania. 7. Department of Surgery, Stanford University, Stanford, CA, USA. 8. Department of Surgery, Emory University, Atlanta, GA, USA. 9. Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal. 10. Department of Surgery, University of Ottawa, Ottawa, ON, Canada. 11. Department of Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia. 12. Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China. 13. Department of Hepatobiliopancreatic Surgery and Liver Transplantation, AP-HP, Beaujon Hospital, Clichy, France. 14. Department of Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands. 15. Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan. 16. Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Tim.Pawlik@osumc.edu. 17. Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Tim.Pawlik@osumc.edu.
Abstract
PURPOSE: To investigate recurrence patterns after surgery for intrahepatic cholangiocarcinoma (ICC) relative to lymph node status, tumor extension, tumor burden score (TBS), and adjuvant chemotherapy. METHODS: Patients who underwent curative-intent resection for ICC from 1990 to 2020 were enrolled from a multi-institutional database. The hazard function was applied to plot the hazard rates over time, with further stratification by T and N AJCC 8th edition categories, TBS, and adjuvant chemotherapy. RESULTS: A total of 1192 patients underwent curative-intent resection for ICC and 59.9% experienced recurrence. Overall, the peak of recurrence occurred at 6.6 months. Among patients with negative lymph nodes, the T4-category had a higher peak rate of recurrence (0.1199 at 10.2 months) compared with other T-categories, while high TBS had an earlier peak of recurrence (4.2 months) compared with lower TBS. Among patients with N1 disease, T2-T4 categories had multipeak patterns of recurrence with higher hazard rates during the first 3 years after surgery in comparison with T1-category, while patients with high TBS had an earlier (4.0 months) and higher hazard peak rate compared with lower TBS groups. The administration of adjuvant chemotherapy was associated with delayed hazard rates of recurrence for N1 (4 months) and NX (6 months) categories. DISCUSSION: The novel application of the hazard function to assess hazard rates and timing patterns of recurrence following resection for ICC demonstrated that recurrence varied based on T- and N-categories, as well as TBS. Hazard function-based recurrence data may be helpful to tailor counseling, surveillance, and adjuvant therapy recommendations.
PURPOSE: To investigate recurrence patterns after surgery for intrahepatic cholangiocarcinoma (ICC) relative to lymph node status, tumor extension, tumor burden score (TBS), and adjuvant chemotherapy. METHODS: Patients who underwent curative-intent resection for ICC from 1990 to 2020 were enrolled from a multi-institutional database. The hazard function was applied to plot the hazard rates over time, with further stratification by T and N AJCC 8th edition categories, TBS, and adjuvant chemotherapy. RESULTS: A total of 1192 patients underwent curative-intent resection for ICC and 59.9% experienced recurrence. Overall, the peak of recurrence occurred at 6.6 months. Among patients with negative lymph nodes, the T4-category had a higher peak rate of recurrence (0.1199 at 10.2 months) compared with other T-categories, while high TBS had an earlier peak of recurrence (4.2 months) compared with lower TBS. Among patients with N1 disease, T2-T4 categories had multipeak patterns of recurrence with higher hazard rates during the first 3 years after surgery in comparison with T1-category, while patients with high TBS had an earlier (4.0 months) and higher hazard peak rate compared with lower TBS groups. The administration of adjuvant chemotherapy was associated with delayed hazard rates of recurrence for N1 (4 months) and NX (6 months) categories. DISCUSSION: The novel application of the hazard function to assess hazard rates and timing patterns of recurrence following resection for ICC demonstrated that recurrence varied based on T- and N-categories, as well as TBS. Hazard function-based recurrence data may be helpful to tailor counseling, surveillance, and adjuvant therapy recommendations.
Authors: Iswanto Sucandy; Shlomi Rayman; Eric C Lai; Chung-Ngai Tang; Yvette Chong; Mikhail Efanov; David Fuks; Gi-Hong Choi; Charing C Chong; Adrian K H Chiow; Marco V Marino; Mikel Prieto; Jae-Hoon Lee; T Peter Kingham; Mathieu D'Hondt; Roberto I Troisi; Sung Hoon Choi; Robert P Sutcliffe; Tan-To Cheung; Fernando Rotellar; James O Park; Olivier Scatton; Ho-Seong Han; Johann Pratschke; Xiaoying Wang; Rong Liu; Brian K P Goh Journal: Ann Surg Oncol Date: 2022-08-23 Impact factor: 4.339